Charles River Laboratories International, Inc. (CRL) is a Medical - Diagnostics & Research company in the Healthcare sector, currently trading at $179.31. It has a SharesGrow Score of 48/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of CRL = $227.39 (+26.8% from the current price, the stock appears undervalued). Analyst consensus target is CRL = $202 (+12.7% upside).
Valuation: CRL trades at a trailing Price-to-Earnings (P/E) of -58.7 (S&P 500 average ~25).
Financials: revenue is $4.0B, -0.9%/yr average growth. Net income is $144M (loss), growing at -533.2%/yr. Net profit margin is -3.6% (negative). Gross margin is 30.5% (-5.9 pp trend).
Balance sheet: total debt is $3.1B against $3.2B equity (Debt-to-Equity (D/E) ratio 0.97, moderate). Current ratio is 1.29 (adequate). Debt-to-assets is 43%. Total assets: $7.1B.
Analyst outlook: 25 / 36 analysts rate CRL as buy (69%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 78/100 (Pass), Growth 15/100 (Fail), Past 75/100 (Partial), Health 50/100 (Partial), Moat 45/100 (Partial), Future 61/100 (Pass), Income 10/100 (Fail).
